Leonardo Roa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leonardo Roa has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Catalina Avendaño
Animal Science Faculty, Universidad de Ciencias Aplicadas y Ambientales (U.D.C.A), Bogotá, Colombia
2 shared publications - Manuel Elkin Patarroyo
Affiliations Molecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Bogotá, Colombia, Microbiology Department, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
2 shared publications - Alejandra Ruiz-Laiton
Animal Science Faculty, Universidad de Ciencias Aplicadas y Ambientales (UDCA), Bogotá D.C., 111166, Colombia
1 shared publication - Alexander Rodríguez-López
Molecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Bogotá D.C., 111321, Colombia
1 shared publication - Ana Carolina Falla
Animal Science Faculty, Universidad de Ciencias Aplicadas y Ambientales (UDCA), Bogotá D.C., 111166, Colombia
1 shared publication - Angie Melissa Puentes-Orozco
Chemistry Programme, Sciences and Education Faculty, Universidad Distrital Francisco José de Caldas, Bogotá D.C., 110321, Colombia; Molecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Bogotá D.C., 111321, Colombia
1 shared publication
Latest Publications
- 3 February 2022
- Published by Elsevier in Preventive Veterinary Medicine
- Vol. 200, 105591
The prevalence of Chlamydia psittaci in confiscated Psittacidae in Colombia
- 3 February 2022
- Published by Elsevier in Preventive Veterinary Medicine
- Vol. 200, 105591
The prevalence of Chlamydia psittaci in confiscated Psittacidae in Colombia
- Open Access
- 2 June 2020
- Published by Instituto Nacional de Investigaciones Forestales Agricolas y Pecuarias in Revista Mexicana de Ciencias Pecuarias
- Vol. 11 (2) , 311-325
Preliminary study of ivermectin residues in bovine livers in the Bogota Savanna
Preliminary study of ivermectin residues in bovine livers in the Bogota Savanna
- 2 June 2020
- Published by Instituto Nacional de Investigaciones Forestales Agricolas y Pecuarias in Revista Mexicana de Ciencias Pecuarias
- Vol. 11 (2) , 311-325
Open AccessPreliminary study of ivermectin residues in bovine livers in the Bogota Savanna
Preliminary study of ivermectin residues in bovine livers in the Bogota Savanna
- Open Access
- 30 December 2019
- Published by Wiley in Journal of Immunology Research
- Vol. 2019, 1-12
Preliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Model
Malaria continues being a high-impact disease regarding public health worldwide; the WHO report for malaria in 2018 estimated that ~219 million cases occurred in 2017, mostly caused by the parasite Plasmodium falciparum. The disease cost the lives of more than 400,000 people, mainly in Africa. In spite of great efforts aimed at developing better prevention (i.e., a highly effective vaccine), diagnosis, and treatment methods for malaria, no efficient solution to this disease has been advanced to date. The Fundación Instituto de Inmunología de Colombia (FIDIC) has been developing studies aimed at furthering the search for vaccine candidates for controlling P. falciparum malaria. However, vaccine development involves safety and immunogenicity studies regarding their formulation in animal models before proceeding to clinical studies. The present work has thus been aimed at evaluating the safety and immunogenicity of a mixture of 23 chemically synthesised, modified peptides (immune protection-inducing protein structure (IMPIPS)) derived from different P. falciparum proteins. Single and repeat dose assays were thus used with male and female BALB/c mice which were immunised with the IMPIPS mixture. It was found that single and repeat dose immunisation with the IMPIPS mixture was safe, both locally and systemically. It was observed that the antibodies so stimulated recognised the parasite’s native proteins and inhibited merozoite invasion of red blood cells in vitro when evaluating the humoral immune response induced by the IMPIPS mixture. Such results suggested that the IMPIPS peptide mixture could be a safe candidate to be tested during the next stage involved in developing an antimalarial vaccine, evaluating local safety, immunogenicity, and protection in a nonhuman primate model.
- 30 December 2019
- Published by Wiley in Journal of Immunology Research
- Vol. 2019, 1-12
Open AccessPreliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Model
Malaria continues being a high-impact disease regarding public health worldwide; the WHO report for malaria in 2018 estimated that ~219 million cases occurred in 2017, mostly caused by the parasite Plasmodium falciparum. The disease cost the lives of more than 400,000 people, mainly in Africa. In spite of great efforts aimed at developing better prevention (i.e., a highly effective vaccine), diagnosis, and treatment methods for malaria, no efficient solution to this disease has been advanced to date. The Fundación Instituto de Inmunología de Colombia (FIDIC) has been developing studies aimed at furthering the search for vaccine candidates for controlling P. falciparum malaria. However, vaccine development involves safety and immunogenicity studies regarding their formulation in animal models before proceeding to clinical studies. The present work has thus been aimed at evaluating the safety and immunogenicity of a mixture of 23 chemically synthesised, modified peptides (immune protection-inducing protein structure (IMPIPS)) derived from different P. falciparum proteins. Single and repeat dose assays were thus used with male and female BALB/c mice which were immunised with the IMPIPS mixture. It was found that single and repeat dose immunisation with the IMPIPS mixture was safe, both locally and systemically. It was observed that the antibodies so stimulated recognised the parasite’s native proteins and inhibited merozoite invasion of red blood cells in vitro when evaluating the humoral immune response induced by the IMPIPS mixture. Such results suggested that the IMPIPS peptide mixture could be a safe candidate to be tested during the next stage involved in developing an antimalarial vaccine, evaluating local safety, immunogenicity, and protection in a nonhuman primate model.